About Oblique Therapeutics

Oblique Therapeutics is a privately held biotech company, founded in 2015 in Gothenburg, Sweden. We are committed to finding treatments for severe diseases with large unmet clinical needs such as pain and aggressive metastatic cancer using our unique angle of a targeted functionality antibody approach.

Asset-generation through our game-changing antibody platform

We are driven by curiosity and innovation to develop a solid portfolio based on asset-generation through our game-changing antibody platform, Abiprot™. Our approach is different: we start with patients and their needs for new medicines. Our goal is to generate novel medicines against any disease-modifying human protein target.

A new beginning for effective targets that failed due to severe toxicity

In most cases, we select targets that have been clinically or genetically validated, often by small molecule approaches, that were highly effective but failed due to severe toxicity. We use our unique platform, Abiprot™, to develop novel therapeutic antibodies against these targets while maintaining efficacy but with a completely different and improved toxicity profile. We also run two programs to address disruptive but scientifically compelling targets.

The platform technology

Our patented biologics platform technology Abiprot™ identifies new therapeutic antibodies that not only bind to a target protein with high specificity and affinity — in many cases they can also be programmed to have a particular pharmacological action. We call these antibodies FTABS™. We believe the technology will enable the development of more effective medicines against target proteins that cannot be addressed with traditional antibody technology. Instead, our technology focuses on GPCRs and ion channels as well as previously undruggable targets.

More than ten programs in the pipeline

Oblique Therapeutics currently has more than ten development programs in the pipeline: five are FTABS™ antibodies obtained with Abiprot™ in areas of pain, advanced cancer and diabetes, while the sixth program involves a small molecule anticancer agent. Of these, three programs are being developed in collaboration with leading pharmaceutical companies in their respective fields.

Five-year outlook and beyond

We have just begun. Our ambitious, but realistic goal is to generate novel medicines against any disease-modifying human protein target. AbiProt™, our biologics platform, has that potential. We welcome proposals for collaboration and our ambition is to run up to half of our programs with pharma companies that hold key competencies in therapeutic areas outside of our scope. We hope to have up to 15 development programs underway in 2022.